CAVALLI, MARZIA
 Distribuzione geografica
Continente #
NA - Nord America 794
EU - Europa 412
AS - Asia 180
AF - Africa 20
SA - Sud America 3
OC - Oceania 1
Totale 1.410
Nazione #
US - Stati Uniti d'America 788
IT - Italia 212
SE - Svezia 112
SG - Singapore 69
CN - Cina 53
IN - India 44
TG - Togo 20
FI - Finlandia 16
DE - Germania 14
BG - Bulgaria 13
GB - Regno Unito 10
ID - Indonesia 7
UA - Ucraina 7
CA - Canada 6
RO - Romania 6
FR - Francia 5
IE - Irlanda 5
AR - Argentina 3
BE - Belgio 3
NL - Olanda 3
CH - Svizzera 2
PH - Filippine 2
AU - Australia 1
BT - Bhutan 1
CZ - Repubblica Ceca 1
HK - Hong Kong 1
KR - Corea 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LU - Lussemburgo 1
LV - Lettonia 1
MY - Malesia 1
Totale 1.410
Città #
Fairfield 119
Chandler 73
Ashburn 65
Rome 64
Singapore 52
Seattle 45
Wilmington 43
Woodbridge 39
Cambridge 37
Beijing 28
Houston 23
Princeton 22
Lomé 20
San Paolo di Civitate 19
New York 15
Ann Arbor 14
Lawrence 14
San Diego 14
Andover 13
Milan 13
Plano 13
Boston 12
Sofia 12
Bremen 10
Santa Clara 10
Trieste 9
Millbury 8
Jakarta 7
Helsinki 6
Naples 6
Chieuti 5
Dublin 5
Florence 5
Southend 5
Bologna 4
Dearborn 4
Ottawa 4
Council Bluffs 3
Genoa 3
Jacksonville 3
Sassari 3
Verona 3
Abano Terme 2
Azzano San Paolo 2
Bareggio 2
Bengaluru 2
Bergamo 2
Brussels 2
Capriva del Friuli 2
Des Moines 2
Federal 2
Ficarolo 2
Freiburg im Breisgau 2
Guidonia Montecelio 2
London 2
Portland 2
Pune 2
Rubano 2
Saint-Fons 2
Salerno 2
Simi Valley 2
Toronto 2
Treviso 2
Vittuone 2
Zhengzhou 2
Almaty 1
Anzio 1
Augusta 1
Bern 1
Boardman 1
Buenos Aires 1
Bühl 1
Caltanissetta 1
Casale Monferrato 1
Casalnuovo di Napoli 1
Catania 1
Central 1
Groningen 1
Handan 1
Hebei 1
Henderson 1
Hounslow 1
Huzhou 1
Lucca 1
Luxembourg 1
Manila 1
Munich 1
Nanjing 1
Norwalk 1
Perugia 1
Phoenix 1
Poggio Renatico 1
Provo 1
Redwood City 1
Riga 1
Santa Maria 1
Schaan 1
Sydney 1
Thimphu 1
Turin 1
Totale 953
Nome #
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimale residual disease-oriented GIMEMA LAL1913 107
Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia 102
A case of late isolated ovarian relapse of acute lymphoblastic leukemia after an allogeneic stem cell transplant. 94
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain react 93
Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma 84
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial 81
Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. 73
Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances 73
Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy 69
Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL). 68
Treatment of early stage follicular lymphoma with involved field radiotherapy and Rituximab. Role of Bcl-2 molecular monitoring. 63
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal? 58
null 54
Linfoma follicolare Stadio I/II:ruolo del monitoraggio molecolare in pazienti trattati con radioterapia locale +/- rituximab. 52
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 50
COMPARISON OF DIFFERENT RQ-PCR DESIGN STRATEGIES FOR MINIMAL RESIDUAL DISEASE EVALUATION IN LYMPHOPROLIFERATIVE DISORDERS: CORRELATION BETWEEN IMMUNOGLOBULIN GENE MUTATION LOAD AND RQ-PCR PERFORMANCE 41
Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia 37
null 36
Prognostic role of BCL-2 molecular monitoring in patients with early stage follicular lymphoma. 34
null 33
Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia 30
A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF-V600E mutation: lack of evidence for a common origin 29
Comparison of different DNA extraction methods from peripheral blood cells: advices from the Fondazione Italiana Linfomi - MRD Network. 29
null 27
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 17
Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia 17
Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia 15
null 15
Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet {PCR} improve measurable residual disease monitoring in chronic lymphoid malignancies? 14
Totale 1.495
Categoria #
all - tutte 5.023
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.023


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020182 0 0 0 0 20 19 32 26 22 28 13 22
2020/2021122 21 19 11 4 3 0 3 14 12 18 9 8
2021/2022302 6 9 20 12 32 8 7 26 19 24 98 41
2022/2023384 48 79 40 25 31 42 2 44 34 7 23 9
2023/2024221 13 36 5 14 17 54 13 17 0 17 25 10
2024/2025123 11 32 28 43 9 0 0 0 0 0 0 0
Totale 1.495